Phase I/II Trial of Motesanib in Combination With Ixabepilone and Capecitabine in Women With Locally Recurrent or Metastatic Breast Cancer.
Withdrawn prior to enrolment
Phase of Trial: Phase I/II
Latest Information Update: 25 Oct 2016
At a glance
- Drugs Motesanib (Primary) ; Capecitabine; Ixabepilone
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 29 Jan 2014 According to ClinicalTrials.gov record, status changed from not yet recruiting to withdrawn prior to recruitment.
- 20 May 2013 Planned initiation date changed from 1 Sep 2012 to 1 Dec 2013 as reported by ClinicalTrials.gov.